Endothelin antagonism as an active principle for glaucoma therapy.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Endothelin antagonism as an active principle for glaucoma therapy.
- Published In:
- British journal of pharmacology, 162(4), 806-16 (2011)
- Authors:
- Rosenthal, Rita, Fromm, Michael
- Database ID:
- RPEP-01846
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01846APA
Rosenthal, Rita; Fromm, Michael. (2011). Endothelin antagonism as an active principle for glaucoma therapy.. British journal of pharmacology, 162(4), 806-16. https://doi.org/10.1111/j.1476-5381.2010.01103.x
MLA
Rosenthal, Rita, et al. "Endothelin antagonism as an active principle for glaucoma therapy.." British journal of pharmacology, 2011. https://doi.org/10.1111/j.1476-5381.2010.01103.x
RethinkPeptides
RethinkPeptides Research Database. "Endothelin antagonism as an active principle for glaucoma th..." RPEP-01846. Retrieved from https://rethinkpeptides.com/research/rosenthal-2011-endothelin-antagonism-as-an
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.